# Pipeline

At Almirall, we are committed to transforming the lives of patients through innovative research and development. Our pipeline represents a broad array of groundbreaking therapies, each designed to address some of the **most pressing medical needs in dermatology**.

## Late stage pipeline

This dynamic pipeline showcases our dedication to advancing treatment options, leveraging cutting-edge science and technology to **bring new solutions to the market**. Here, you can explore our Late-stage pipeline, where we focus on delivering therapies that promise to make a meaningful impact on patient care.

Last update: 29 July 2026

| Name                    | Indication                                  | Type                    | Phase   | Region       |
|-------------------------|--------------------------------------------|-------------------------|---------|--------------|
| Tirbanibulin           | Actinic keratosis                          | Life-cycle management   | Registration | European Union |
| Lebrikizumab           | Paediatric atopic dermatitis               | Life-cycle management   | Phase III | European Union |
| Lebrikizumab           | Nummular eczema                            | Life-cycle management   | Phase III | European Union |
| Anti-IL-1RAP mAb      | Hidradenitis suppurativa                   | New Molecular Entity    | Phase II | Worldwide     |
| Anti-IL-1RAP mAb      | Inflammatory skin disease                   | New Molecular Entity    | Phase II | Worldwide     |
| Anti-IL-21 mAb        | Hidradenitis suppurativa                   | New Molecular Entity    | Phase II | Worldwide     |
| IL-2muFc              | SLE with cutaneous manifestations          | New Molecular Entity    | Phase II | Worldwide     |
| IL-2muFc              | Atopic dermatitis                          | New Molecular Entity    | Phase II | Worldwide     |
| IL-2muFc              | Alopecia areata                            | New Molecular Entity    | Phase II | Worldwide     |
| Readthrough inducer    | Rare dermatology (RDEB/JEB)               | New Molecular Entity    | Phase I  | Worldwide     |
| Anti-IL-13/OX40L BsAb | Atopic dermatitis                          | New Molecular Entity    | Phase I  | Worldwide     |
| SMOL oral              | Th2-driven diseases                        | New Molecular Entity    | Preclinical | Worldwide   |
| mRNA/LNP              | Non-melanoma skin cancer                   | New Molecular Entity    | Preclinical | Worldwide   |